Patents by Inventor Mike Byrom

Mike Byrom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20150004221
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: August 13, 2014
    Publication date: January 1, 2015
    Applicant: ASURAGEN, INC.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20150005366
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: August 13, 2014
    Publication date: January 1, 2015
    Applicant: ASURAGEN, INC.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • System and method for electroporating a sample
    Patent number: 8921092
    Abstract: A system and method are described for electroporating a sample that utilizes one or more sets of electrodes that are spaced apart in order to hold a surface tension constrained sample between the electrodes. The first electrode is connected to the lower body of the system while the second electrode is connected to the upper body. Both electrodes are connected to a pulse generator. Each electrode has a sample contact surface such that the first electrode and the second electrode may be positioned to hold a surface tension constrained sample between the two sample contact surfaces and the sample may receive a selected electric pulse.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: December 30, 2014
    Assignee: Applied Biosystems LLC
    Inventors: Richard Jarvis, Mike Byrom, Dmitriy Ovcharenko
  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20140348907
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: August 13, 2014
    Publication date: November 27, 2014
    Applicant: ASURAGEN, INC.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20140348908
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: August 13, 2014
    Publication date: November 27, 2014
    Applicant: ASURAGEN, INC.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20140350086
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: August 13, 2014
    Publication date: November 27, 2014
    Applicant: ASURAGEN, INC.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20140314833
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: April 16, 2014
    Publication date: October 23, 2014
    Applicant: Mirna Therapeutics, Inc.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • Methods and compositions involving miRNA and miRNA inhibitor molecules
    Patent number: 8765709
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: July 1, 2014
    Assignee: Asuragen, Inc.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20140031415
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: August 28, 2013
    Publication date: January 30, 2014
    Applicant: ASURAGEN, INC.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20130303591
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: May 3, 2013
    Publication date: November 14, 2013
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitry Ovcharenko, Eric Devroe, Kevin Kelnar
  • Methods and compositions involving miRNA and miRNA inhibitor molecules
    Patent number: 8563708
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: October 22, 2013
    Assignee: Asuragen, Inc.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • System and method for electroporating a sample
    Patent number: 8383394
    Abstract: A system and method are described for electroporating a sample that utilizes one or more sets of electrodes that are spaced apart in order to hold a surface tension constrained sample between the electrodes. The first electrode is connected to the lower body of the system while the second electrode is connected to the upper body. Both electrodes are connected to a pulse generator. Each electrode has a sample contact surface such that the first electrode and the second electrode may be positioned to hold a surface tension constrained sample between the two sample contact surfaces and the sample may receive a selected electric pulse.
    Type: Grant
    Filed: April 14, 2010
    Date of Patent: February 26, 2013
    Assignee: Applied Biosystems, LLC
    Inventors: Richard Jarvis, Mike Byrom, Dmitriy Ovcharenko
  • Methods and compositions involving miRNA and miRNA inhibitor molecules
    Patent number: 8173611
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: May 8, 2012
    Assignee: Asuragen Inc.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20120065248
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: November 17, 2011
    Publication date: March 15, 2012
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
    Publication number: 20110313025
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Application
    Filed: July 25, 2011
    Publication date: December 22, 2011
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • MiR-124 regulated genes and pathways as targets for therapeutic intervention
    Patent number: 8071562
    Abstract: The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-124, using miR-124 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.
    Type: Grant
    Filed: December 1, 2008
    Date of Patent: December 6, 2011
    Assignee: Mirna Therapeutics, Inc.
    Inventors: Andreas G. Bader, Jason F. Wiggins, Lubna Patrawala, Kevin Kelnar, Mike Byrom, David Brown
  • Methods and compositions involving miRNA and miRNA inhibitor molecules
    Patent number: 8058250
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: November 15, 2011
    Assignee: Asuragen, Inc.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • Methods and compositions involving miRNA and miRNA inhibitor molecules
    Patent number: 7960359
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: June 14, 2011
    Assignee: Asuragen, Inc.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • METHODS AND COMPOSITIONS RELATING TO LABELED RNA MOLECULES THAT REDUCE GENE EXPRESSION
    Publication number: 20100184039
    Abstract: The present invention concerns methods and compositions involving labeled, double-stranded RNA (dsRNA), including siRNA, capable of triggering RNA-mediated interference (RNAi) in a cell. Compositions of the invention include labeled dsRNA for RNAi, which may be a single strand of RNA that basepairs with itself or two separate RNA strands. In some embodiments, the label is fluorescent. The present invention further concerns methods for preparing such composition and kits for implementing such methods. Other methods of the invention include ways of using labeled dsRNA for RNAi.
    Type: Application
    Filed: September 28, 2009
    Publication date: July 22, 2010
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Lance P. Ford, Mike Byrom, Brittan L. Pasloske
  • miR-21 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
    Publication number: 20090192102
    Abstract: The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-21, using miR-21 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.
    Type: Application
    Filed: May 14, 2008
    Publication date: July 30, 2009
    Inventors: Andreas G. Bader, Mike Byrom, Charles D. Johnson, David Brown